🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. RYMPHYSIA

    Takeda

    Chronic Obstructive Pulmonary Disease (COPD)

    approved mab terminated

    1 trial

  2. Ramelteon

    Takeda

    ADHD With Sleep Onset Insomnia

    approved small molecule completed

    1 trial

  3. Ramelteon

    Takeda

    Bipolar Disorder

    approved small molecule terminated

    2 trials

  4. Ramelteon

    Takeda

    Chronic Insomnia

    approved small molecule completed

    7 trials

  5. Ramelteon

    Takeda

    Circadian Dysregulation

    approved small molecule completed

    1 trial

  6. Ramelteon

    Takeda

    Insomnia

    approved small molecule completed

    6 trials

  7. Ramelteon

    Takeda

    Seasonal Affective Disorder

    approved small molecule completed

    1 trial

  8. Ramelteon

    Takeda

    Schizophrenia

    approved small molecule completed

    1 trial

  9. Ramelteon (RozeremR)

    Takeda

    Insomnia

    approved small molecule terminated

    1 trial

  10. Ramelteon and Placebo

    Takeda

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    2 trials

  11. Ramelteon and zolpidem

    Takeda

    Chronic Insomnia

    approved small molecule completed

    1 trial

  12. Ramelteon, zolpidem and placebo

    Takeda

    Insomnia

    approved small molecule completed

    1 trial

  13. Recombinant Protein-Free Factor VIII (rAHF-PFM)

    Takeda

    Hemophilia A

    approved small molecule completed

    1 trial

  14. SPD489

    Takeda

    ADHD Specifically With Executive Function Impairment

    approved small molecule completed

    1 trial

  15. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    approved small molecule completed

    1 trial

  16. TACHOSIL GROUP

    Takeda

    Lymphocele

    approved mab completed

    1 trial

  17. TAK-085

    Takeda

    Hyperlipidemia

    approved small molecule completed

    2 trials

  18. Tinoridine HCl

    Takeda

    Pain

    approved small molecule completed

    1 trial

  19. Treatment Algorithm A

    Takeda

    Colitis, Ulcerative

    approved mab active

    1 trial

  20. Trelagliptin

    Takeda

    Type 2 Diabetes

    approved small molecule completed

    1 trial

  21. Trelagliptin

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    2 trials

  22. Vedolizumab

    Takeda

    Crohn's Disease

    approved small molecule active

    6 trials

  23. Vedolizumab

    Takeda

    Crohn Disease

    approved small molecule terminated

    4 trials

  24. Vedolizumab

    Takeda

    Moderately to Severely Active Crohn's Disease

    approved mab active

    1 trial

  25. Vedolizumab 300 mg

    Takeda

    Colitis, Ulcerative

    approved small molecule completed

    1 trial

  26. Vedolizumab IV

    Takeda

    Colitis, Ulcerative

    approved small molecule completed

    1 trial

  27. Vedolizumab Placebo

    Takeda

    Pouchitis

    approved small molecule completed

    1 trial

  28. Velaglucerase Alfa

    Takeda

    Gaucher Disease

    approved small molecule completed

    4 trials

  29. Vonoprazan

    Takeda

    Reflux Esophagitis

    approved small molecule completed

    1 trial

  30. Vonoprazan

    Takeda

    Erosive Esophagitis

    approved small molecule completed

    3 trials

  31. Vortioxetine

    Takeda

    Unipolar Major Depression

    approved small molecule terminated

    1 trial

  32. Vortioxetine

    Takeda

    Depressive Disorder

    approved small molecule terminated

    1 trial

  33. Vortioxetine

    Takeda

    Schizophrenia

    approved small molecule active

    1 trial

  34. Vortioxetine

    Takeda

    Healthy Volunteers

    approved small molecule completed

    1 trial

  35. Vortioxetine

    Takeda

    Type2 Diabetes

    approved small molecule terminated

    1 trial

  36. Vortioxetine 10 mg

    Takeda

    Age-related Cognitive Decline

    approved small molecule completed

    1 trial

  37. Vyvanse (lisdexamfetamine dimesylate)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    approved small molecule completed

    1 trial

  38. alogliptin+pioglitazone

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

  39. aspirin and/or clopidogrel

    Takeda

    Early Gastric Cancer

    approved small molecule active

    1 trial

  40. dexlansoprazole

    Takeda

    Laryngopharyngeal Reflux

    approved small molecule active

    1 trial

  41. lubiprostone

    Takeda

    Healthy

    approved small molecule completed

    1 trial

  42. lubiprostone

    Takeda

    Chronic Idiopathic Constipation

    approved small molecule completed

    3 trials

  43. lubiprostone (Amitiza)

    Takeda

    Colonoscopy

    approved small molecule completed

    1 trial

  44. midodrine hydrochloride (ProAmatine®)

    Takeda

    Hypotension, Orthostatic

    approved small molecule terminated

    1 trial

  45. pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    4 trials

  46. pioglitazone

    Takeda

    Type 2 Diabetes

    approved small molecule completed

    1 trial

  47. placebo

    Takeda

    Constipation

    approved small molecule completed

    1 trial

  48. prucalopride

    Takeda

    Chronic Constipation

    approved small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.